Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vicriviroc - Merck & Co

Next Previous
X
Search
Drug Profile

Vicriviroc - Merck & Co

Alternative Names: MK-7690; SCH-417; SCH-417690; SCH-D; Schering-D

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co
  • Class Antineoplastics; Antiretrovirals; Fluorinated hydrocarbons; Piperazines; Pyrimidines
  • Mechanism of Action CCR5 receptor antagonists; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • Discontinued HIV-1 infections

Most Recent Events

  • 08 Jun 2021 Merck completes Phase-II clinical trials in Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in USA and Canada (PO) (NCT03631407)
  • 18 Feb 2021 Vicriviroc is still in phase II trials for Colorectal cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA and Canada (PO) (NCT03631407)
  • 12 Sep 2019 Merck withdraws the phase III VICTOR-E2 trial in HIV-1 infections (Combination therapy, Treatment experienced) prior to enrolment (NCT00243568)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top